Skip to main content
SYS · ONLINEPASS · 63.0%
Open Assay
Independent Testing / Est. 2026
BATCH04·26·B
PASS63.0%
N27
PeptidesLongevitySpermidine

Spermidine

/ Endogenous polyamine; autophagy inducer (small molecule)
TIER 3 · PreclinicalN = 0 · TESTING PENDINGMW 145.25 g·mol⁻¹

ALIAS · Spermidine · N1-(3-aminopropyl)butane-1,4-diamine

Pass rate
0
Samples
0
Suppliers
Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity
Primary sequence— sequence not captured —
MW · 145.25CLASS · Endogenous polyamine; autophagy inducer (small molecule)CATEGORY · Longevity

Tier 3. The strongest geroscience evidence is murine: Eisenberg and colleagues (2016) reported dietary spermidine supplementation extended lifespan in mice and reduced cardiac hypertrophy. Human evidence is limited to small cohort and trial data — most prominently the SmartAge trial of spermidine in older adults with subjective cognitive decline (Schwarz and colleagues 2018). Sold widely as a supplement (wheat germ extract is the predominant commercial source) under the US DSHEA framework; not FDA-approved for any indication.

§ B · Mechanism of action

Spermidine is an endogenous triamine (1,4-diaminobutane with an aminopropyl substituent on N1) and one of three principal mammalian polyamines alongside putrescine and spermine. Spermidine is the unique substrate for hypusine modification of eukaryotic translation initiation factor 5A (eIF5A), an essential post-translational modification required for translation of polyproline-rich proteins.

The geroscience interest derives primarily from spermidine's capacity to induce macroautophagy through inhibition of cytoplasmic histone acetyltransferases (notably EP300), shifting the cellular acetylation balance toward histone deacetylation and de-repressing autophagy gene transcription. Endogenous tissue spermidine declines with age in multiple mammalian models; supplementation is hypothesised to restore polyamine pools and re-establish autophagic flux. Dietary sources include wheat germ, fermented soybean products, and aged cheese; commercial supplement formulations are predominantly wheat germ-derived spermidine concentrates.

§ C · Human clinical evidence

Tier 3. Eisenberg and colleagues (2016) reported lifelong dietary spermidine supplementation extended median and maximum lifespan in mice, with reductions in cardiac hypertrophy and improvements in arterial function — the foundational mammalian lifespan study. The SmartAge trial (Schwarz and colleagues 2018) randomised 30 older adults with subjective cognitive decline to spermidine-rich wheat germ extract or placebo for three months and reported modest improvements in memory performance.

§ D · Primary literature
PubMed27841876Eisenberg T et al.Cardioprotection and lifespan extension by the natural polyamine spermidine · Nature Medicine · rodentLifelong dietary spermidine extended median and maximum lifespan in two mouse strains, reduced cardiac hypertrophy and diastolic dysfunction, and produced epidemiological signals consistent with cardiovascular benefit in human cohort data.Limitations: Murine lifespan as primary endpoint; human data limited to observational cohort signal.2016
PubMed29315079Schwarz C et al.Safety and tolerability of spermidine supplementation in mice and older adults with subjective cognitive decline · Aging · human-phase-2Three months of spermidine-rich wheat germ extract supplementation was well-tolerated in older adults with subjective cognitive decline and produced modest improvements on memory performance measures versus placebo.Limitations: Small n; three-month duration; subjective cognitive decline cohort rather than dementia.2018
PubMed29371440Madeo F et al.Spermidine in health and disease · Science · reviewComprehensive review of spermidine biology, autophagy mechanism, age-related polyamine decline, and the experimental and observational evidence base linking spermidine to longevity and cardiovascular outcomes.Limitations: Narrative review; emphasises the supportive evidence base; long-term human outcome data sparse.2018
§ F · Safety signal

Generally well-tolerated in published trial doses. Reported adverse events at the trial doses studied (1-2 mg spermidine equivalent daily from wheat germ extract) include mild gastrointestinal upset. Food-source spermidine intake in normal Western diets is typically several-fold higher than supplement doses without identified safety issues. Long-term safety of concentrated supplement formulations beyond the durations studied has not been characterised.

§ H · Regulatory status

Regulatory status

FDA status:
Not FDA-approved
§ I · Notable gaps and controversies

Long-term outcome data are sparse. The SmartAge cognitive results are from a small short-duration trial; the murine lifespan finding is the most robust geroscience datapoint but does not directly demonstrate human longevity benefit. The supplement category includes products of variable spermidine content and concentration; vendor product specifications and analytical certificates of analysis vary substantially. Some interest has focused on whether plasma or tissue spermidine is the relevant pharmacodynamic readout, and whether wheat germ extract delivers meaningful spermidine to target tissues — questions not yet resolved by the current clinical trial literature.